跳至主要内容
临床试验/NCT00071032
NCT00071032已完成3 期

Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS)

Rutgers, The State University of New Jersey2 个研究点 分布在 1 个国家目标入组 2,016 人开始时间: 2003年7月最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
2,016
试验地点
2
主要终点
Inability to Walk 10 Feet or Across a Room Without Human Assistance or Death

研究概览

简要总结

The purpose of this study is to compare liberal red blood cell transfusion therapy with restrictive red blood cell transfusion therapy in surgical patients with cardiovascular disease or risk factors.

详细描述

BACKGROUND:

Red blood cell transfusions are an extremely common medical intervention in both the United States and worldwide; over 14 million units of blood are transfused in the United States. Between 60 and 70 percent of all blood is transfused in the surgical setting. Despite the common use of red blood cell transfusions, the threshold for transfusion has not been adequately evaluated and is very controversial. A decade ago, the standard of care was to administer a peri-operative transfusion whenever the hemoglobin (Hgb) level fell below 10 g/dl (the "10/30 rule"). Concerns about the safety of blood, especially with respect to HIV and hepatitis, and the absence of data to support a 10 g/dl threshold led to the current standard of care, which is to administer blood transfusions based on the presence of symptoms, and not a specific Hgb/hematocrit level. However, there have not been any randomized clinical trials done with surgical patients that have tested the efficacy and safety of withholding blood until the patient develops symptoms, or the "10/30" approach to transfusion. Patients with underlying cardiovascular disease are at greatest risk of adverse effects from reduced Hgb levels.

DESIGN NARRATIVE:

This is a multi-center randomized trial to test the effectiveness of a transfusion strategy that maintains postoperative Hgb levels above 10 g/dl (liberal transfusion) in improving patient outcome. This will be compared to the restrictive (symptomatic) transfusion strategy in which blood transfusion is withheld until the patient develops symptoms of anemia or Hgb less than 8 g/dL. Participants will be randomly assigned to one of the two transfusion strategies. The liberal (10 g/dl) threshold strategy will use enough red blood cell units to maintain Hgb levels at or above 10 g/dl through hospital discharge. Restrictive (Symptomatic) transfusion strategy patients will receive red blood cell transfusions for symptoms of anemia, although transfusion is also permitted, but not required, if the Hgb level falls below 8 g/dl. Outcomes will include functional recovery (primary outcome: ability to walk 10 feet across a room without human assistance or death 60 days post-randomization), lower extremity activities of daily living and instrumental activities of daily living, survival up to 60-days and long-term, disposition (i.e., nursing home placement), and postoperative complications (e.g., myocardial infarction, unstable angina, or death in hospital, pneumonia, wound infection, thromboembolism, stroke).

Ambulation at 60 days is known to be highly predictive of ultimate functional outcome as well as of mortality at one year. Because inability to walk has such important implications for quality of life, and because it is a common problem, it far outweighs the small risk of viral infection or other complications from transfusion in elderly patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Has undergone surgical repair for a hip fracture
  • Has a postoperative Hgb level below 10 g/dL within three days of surgery
  • Diagnosis of cardiovascular disease (e.g., coronary artery disease, congestive heart failure, stroke or transient ischemic attack, or peripheral vascular disease) or cardiovascular risk factors (e.g., diabetes mellitus, hypertension, hypercholesterolemia, tobacco use, or creatinine levels greater than 2.0 mg/dL)

排除标准

  • Unable to walk prior to hip fracture
  • Declines blood transfusions
  • Suffered multiple traumas
  • Pathologic fracture of the hip due to malignancy
  • Clinically recognized acute myocardial infarction within the 30 days prior to study entry
  • Previously participated in the trial and fractured the other hip
  • Symptoms associated with anemia (e.g., ischemic chest pain) or actively bleeding at the time of randomization

结局指标

主要结局

Inability to Walk 10 Feet or Across a Room Without Human Assistance or Death

时间窗: 60 days after randomization

ascertained via telephone follow-up

次要结局

  • Myocardial Infarction, Unstable Angina, or Death for Any Reason(In-hospital)
  • Disposition Status (i.e., Nursing Home Placement)(60 days)
  • Function - Lower Extremity Activities of Daily Living,at 30 Days(30 days)
  • Function - Instrumental Activities of Daily Living, at 60 Days(60 Days)
  • Length of Stay in Hospital for United States Participants(Days from randomization to discharge)
  • Function - Instrumental Activities of Daily Living, at 30 Days(30 days)
  • Function - Lower Extremity Activities of Daily Living. at 60 Days(60 Days)
  • Length of Stay in Hospital for Canadian Participants(Days from randomization to discharge)
  • Function - Fatigue/Energy, at 30 Days(30 days)
  • Mortality at 30 Days(30 days)
  • Mortality at 60 Days(60 Days)
  • Composite Outcomes (a) Death, Myocardial Infarction, or Pneumonia and b) Death, Myocardial Infarction, Pneumonia, Thromboembolism, or Stroke(In-hospital)
  • Myocardial Infarction(In-hospital)
  • Function - Fatigue/Energy, at 60 Days(60 Days)
  • Postoperative Complications (e.g., Wound Infection, Thromboembolism, Stroke)(In hospital)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jeffrey L Carson, MD

Jeffrey L Carson

Rutgers, The State University of New Jersey

研究点 (2)

Loading locations...

相似试验